StreetAlpha.app
Home › Stocks › DTIL

Precision Biosciences Inc (DTIL)

$7.40
▲ +7.09%
LAST CLOSE · NOV 20

Precision BioSciences develops gene editing treatments for genetic and infectious diseases using its ARCUS platform. It last closed at $7.40 on Nov 20, up 7.09% on the day. The next earnings report for DTIL is expected around Tue, Jan 12, 2027, after the close. For the quarter ended Sep 2026, DTIL reported EPS of -$0.28 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months DTIL insiders bought $63K of stock on the open market and sold $459K, according to SEC Form 4 filings.

AI Auto Pilots
Is DTIL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DTIL.

Key Stats

Last 12 months
Results
Revenue
$45.0M
+6353.0% vs a year ago
Net income
−$38.5M
−85.6% margin
Free cash flow
−$51.8M
−115.0% margin
Operating margin
−80.3%
−$36.2M operating income
Valuation
Market cap
$206.7M
27.9M shares
P/E
–
Price to sales
4.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$81.7M
At Sep 30
Shareholder equity
$51.8M
Shares outstanding
27.9M
At Oct 29
Fiscal year endsMay
ExchangeNasdaq
Financials history
FY2021: $115.5M$115.5MFY2021FY2022: $25.1M$25.1MFY2022FY2023: $48.7M$48.7MFY2023FY2024: $68.7M$68.7MFY2024FY2025: $34.3M$34.3MFY2025

From DTIL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Jan 12
Estimated date · After the close
Reported EPS
-$0.28
Quarter ended Sep 2026
Year ago EPS
-$1.84
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.74Dec '24Mar 2025: -$2.21Mar '25Jun 2025: -$2.13Jun '25Sep 2025: -$1.84Sep '25Dec 2025: $2.58Dec '25Mar 2026: -$0.75Mar '26Jun 2026: -$1.26Jun '26Sep 2026: -$0.28Sep '26Latest -$0.28
Revenue by quarter
Dec 2024: $638,000Dec '24Mar 2025: $29,000Mar '25Jun 2025: $18,000Jun '25Sep 2025: $13,000Sep '25Dec 2025: $34.2MDec '25Mar 2026: $10.8MMar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How DTIL moved after its last 8 reports
Average move the session after a report ±4.8%
Nov 3, 2026Time not announced+0.3%
Aug 6, 2026Time not announced−0.7%
May 5, 2026Time not announced−2.4%
Mar 12, 2026Time not announced+12.1%
Jan 13, 2026After the close+0.5%
Nov 3, 2025Time not announced−9.8%
Aug 7, 2025Time not announced−5.0%
May 15, 2025Time not announced−8.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DTILStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DTIL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DTIL

Technical Analysis

DTIL · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 7% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot at $7.24, and the nearest resistance the 100 day average at $7.41.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 9.8%/day
Key levels
$11.2952 week high+52.6%
$7.8720 day average+6.4%
$7.73Swing high (Jul 27)+4.5%
$7.71Pivot R1+4.2%
$7.41100 day average+0.1%
$7.40Last close
$7.24Pivot−2.2%
$7.18Swing low (Aug 14)−3.0%
$7.0050 day average−5.4%
$6.93Pivot S1−6.4%
$6.85200 day average−7.4%
$3.5352 week low−52.3%
Indicators
RSI (14)48.52Middle of its rangeNeutral
MACD0.09Below its signal lineBearish
Stochastic10.7Near the bottom of its rangeOversold
ADX (14)18.9No clear trend
Williams %R-83.7Oversold below −80, overbought above −20Oversold
CCI (20)-43.4Oversold below −100, overbought above 100Neutral
Rate of change−30.2%Change over 10 sessionsBearish
ATR (14)$0.73Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for DTIL

What happened before

See how DTIL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DTIL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DTIL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DTILHow many large options trades hit DTIL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

DTIL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲54 buying vs 33 selling
  • ▲Held by funds +6.3 pts
  • ▲Funds holding +13
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10996+13.5%
In funds' top 1013−66.7%
Held by funds69.8%63.5%+6.3 pts
New / increased20 / 3431 / 31−12.9%
Reduced / sold out26 / 714 / 13+22.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DTIL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DTIL Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$63K6 buys · 3 insiders
Sold$459K9 sales · 4 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 bought $34K2026-01 sold $283K2026-02 sold $148K2026-09 bought $30K2026-11 sold $28KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 10Dario ScimecaChief Legal OfficerSale plan2,821$9.75$28K
Sep 28Stanley FrankelDirectorBuy1,000$6.00$6K
Sep 25Geno J GermanoDirectorBuy2,609$6.28$16K
Sep 25Melinda BrownDirectorBuy1,135$6.27$7K
Feb 18J. Jefferson SmithChief Research OfficerSale plan4,925$3.84$19K
Feb 18Dario ScimecaGeneral Counsel and SecretarySale plan4,925$3.84$19K
Every insider buy and sale for DTIL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DTIL insider trades →

From SEC Form 4 filings by DTIL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DTIL is in one of them and how their past DTIL trades turned out.

DTIL in the AI portfolios
Loading…

DTIL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DTIL in an article yet. Here's the latest on the wider market.

DTIL in the news

About Precision Biosciences

Precision BioSciences is a gene editing company based in Durham, North Carolina. It uses its ARCUS platform, a gene editing tool built on a single protein, to develop treatments for genetic and infectious diseases. Its lead programs target chronic hepatitis B and Duchenne muscular dystrophy, and it also partners with iECURE on a treatment for ornithine transcarbamylase deficiency. The company's work is aimed at patients with these serious conditions.

Headquarters
Durham, NC